Matthew Matasar, MD

please fine me at BlueSky - not here on twitter/x any more

[Matthew Matasar, MD @DrMatasar]

This will be my last post here for presumably some time. I can’t in good conscience remain on this platform. Time to figure out BlueSky. There is so much wrong with our society right now, almost all beyond my control. But for me remaining on Twitter has become unconscionable.

[Matthew Matasar, MD @DrMatasar]

@galeabrewer @nyagandmarkets It’s Saturday 2pm, and Barzini’s is still open and serving unwitting customers. Why?!

[CancerNetwork® @CancerNetwrk]

Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma. #lymsm | @DrMatasar

https://t.co/xmPtnqwgCs

[CancerTherapyAdvisor @CancerTherAdvsr]

Advances in MCL and FL from #ASH24. With
@SehnLaurie of @BCCancer, @timfenske of @MedicalCollege, @poh_christina of @fredhutch & @UW, Dr Sunita Nasta of @PennCancer, @LymphClinician of @cityofhope, @DrMatasar of @RutgersCancer, and more. #lymsm https://t.co/SrtEqdxDTQ

[Matthew Matasar, MD @DrMatasar]

Odronextamab post-CAR: glad to have shared our updated data from #ELM1 with @OncLearnNetwork at #ASH24 https://t.co/PeDrueRiir

[Rutgers Cancer Institute @RutgersCancer]

Don’t miss @DrMatasar’s oral presentation today at #ASH24 highlighting innovative findings from the ELM-1 study on the efficacy and safety of odronextamab monotherapy for patients with relapsed/refractory #DLBCL. Learn more about the research here: https://t.co/ctK1cRsQiV

[Matthew Matasar, MD @DrMatasar]

#ASH24 come check out the VR and digital avatars with Encompass - moving education around bispecifics into the future!

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

👏👏 Kudos to adult & pediatric Chiefs @DrMatasar & Peter Cole for GREAT achievement at the @ASH_hematology #hematology symposium this year (6⃣6⃣ at the 6⃣6⃣th #ASH24).

🎉🎉An extra call-out to @drjoannarhodes1 directing the #lymphoma program to nearly 50 lymphoid presentations!

[Matthew Matasar, MD @DrMatasar]

@OncoAdvLukas @TargetedOnc @JenCrombieMD @DanaFarber @harvardmed @RutgersCancer Couldn’t agree more!

[Matthew Matasar, MD @DrMatasar]

Hope to see you at #ASH24 - should be a great session alongside superstars 💫 @chanyooncheah @UjjaniC @nishjo76 and @End_myeloma 💫

[MedscapeLIVE @MedscapeLIVE]

📊 Stay updated on the standards of care for hematologic malignancies and enhance your skills in community-based management. 💉 Gain confidence in tailoring patient-centric treatment plans for optimal outcomes. Join our expert @DrMatasar 📍 https://t.co/0iaiQ29Zn8

#ASH24

[Targeted Oncology @TargetedOnc]

Exploring the Management of Cytokine Release Syndrome With @JenCrombieMD @DanaFarber @harvardmed and @DrMatasar @RutgersCancer

https://t.co/i60lkwI94l

[Matthew Matasar, MD @DrMatasar]

Great conversation with @JenCrombieMD about #bispecifics #bsab with a focus on deploying them in community settings!

[Targeted Oncology @TargetedOnc]

In this series, experts discuss how to operationalize bispecific antibody therapy in community practices. @JenCrombieMD @DanaFarber @harvardmed @DrMatasar @RutgersCancer @missioncancer_

https://t.co/DYbzS9jVAp

[MedscapeLIVE @MedscapeLIVE]

📊 Stay updated on the standards of care for hematologic malignancies and enhance your skills in community-based management. 💉 Gain confidence in tailoring patient-centric treatment plans for optimal outcomes. Join our expert @DrMatasar 📍 https://t.co/0iaiQ29Zn8

#ASH24

[Matthew Matasar, MD @DrMatasar]

Enjoyed talking with @JenCrombieMD about the present (and future!) of #bispecifics in B-cell lymphoma!

[Targeted Oncology @TargetedOnc]

Experts discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T-cell engagement and targeting malignant B cells effectively. @JenCrombieMD @DanaFarber @RutgersCancer

https://t.co/BG2yLT2vRG

[Matthew Matasar, MD @DrMatasar]

@RutgersCancer Heme Team outing with the @SOMPatriots - gorgeous evening with the BEST people

[Matthew Matasar, MD @DrMatasar]

Proud to share that @RutgersCancer has successfully treated our 200th patient with #CART therapy. And we’re only getting started, with NJ’s only CAR-T GMP facility and leadership in innovative clinical trials! https://t.co/02TOUqp83p

[Matthew Matasar, MD @DrMatasar]

Way to go Dr.Tiger! @WomenInLymphoma #risingstar

[Matthew Matasar, MD @DrMatasar]

Looking forward to today's session on the evolving role for #BTK inhibitors in first-line treatment of #MCL with my friend and MCL expert Dr. Anita Kumar (not on twitter!) @medliveofficial https://t.co/GNgZnAIf41

[Matthew Matasar, MD @DrMatasar]

OLYMPIA-3 is a trial-in-progress for patients with newly diagnosed DLBCL evaluating O-CHOP (odronextamab + chop). Spoke with @OncLearnNetwork to give the skinny - thrilled to be trying to move #bispecifics to the first line! @Regeneron
https://t.co/yqemMtMYoS